Kathleen Wilson-Edell, PhD
Sr Officer Engmt and Opp Dev
Innovation Ventures
Chancellor/EVC/FAS

Kathy joined the UCSF Office of Technology Management(OTM) in March of 2014. She works with UCSF faculty members to protect intellectual property arising from their research and negotiates licenses to these technologies with both startups and established companies.

Show full bio (100 words) Hide full bio

Prior to joining OTM full-time, Kathy was a part-time Technology Analyst with UCSF OTM while completing her postdoctoral training at the Buck Institute for Research on Aging in Dr. Christopher Benz’s laboratory. Her postdoctoral research focused on the role of ribosomal proteins in breast cancer. She received her Ph.D. in Genetics from Yale University in Dr. David Stern’s laboratory, studying regulation of gene expression and cytoskeleton rearrangement by BRCA1-related proteins. Kathy’s A.B. is from Cornell University, where she was a Presidential Research Scholar.

Kathy is passionate about helping UCSF investigators move their discoveries from the laboratory to the public domain.

Education & Training

Show all (2) Hide

• Ph.D. Genetics Yale University 2009
• A.B. Biology Cornell University 2004

Publications (9)

Top publication keywords:
Tumor Suppressor ProteinsRibosomal ProteinsNuclear ProteinsHistone Deacetylase InhibitorsHydroxamic AcidsTrans-ActivatorsBRCA1 ProteinCaveolin 1PolyribosomesTOR Serine-Threonine KinasesRNA InterferenceMultiprotein ComplexesProto-Oncogene Proteins c-aktHistone DeacetylasesCaveolin 2

• Author Correction: MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.
  Nature cell biology 2021 Laberge RM, Sun Y, Orjalo AV, Patil CK, Freund A, Zhou L, Curran SC, Davalos AR, Wilson-Edell KA, Liu S, Limbad C, Demaria M, Li P, Hubbard GB, Ikeno Y, Javors M, Desprez PY, Benz CC, Kapahi P, Nelson…
• MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.
  Nature cell biology 2015 Laberge RM, Sun Y, Orjalo AV, Patil CK, Freund A, Zhou L, Curran SC, Davalos AR, Wilson-Edell KA, Liu S, Limbad C, Demaria M, Li P, Hubbard GB, Ikeno Y, Javors M, Desprez PY, Benz CC, Kapahi P, Nelson…
• RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth.
  Oncotarget 2014 Wilson-Edell KA, Kehasse A, Scott GK, Yau C, Rothschild DE, Schilling B, Gabriel BS, Yevtushenko MA, Hanson IM, Held JM, Gibson BW, Benz CC
• mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
  Breast cancer research and treatment 2014 Wilson-Edell KA, Yevtushenko MA, Rothschild DE, Rogers AN, Benz CC
• NFBD1/MDC1 regulates Cav1 and Cav2 independently of DNA damage and p53.
  Molecular cancer research : MCR 2011 Wilson KA, Colavito SA, Schulz V, Wakefield PH, Sessa W, Tuck D, Stern DF

Show all (4 more) Hide

• NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathway.
  Cell cycle (Georgetown, Tex.) 2008 Wilson KA, Stern DF
• Intracellular trafficking of vitamin E in hepatocytes: the role of tocopherol transfer protein.
  Journal of lipid research 2005 Qian J, Morley S, Wilson K, Nava P, Atkinson J, Manor D
• Intracellular localization of alpha-tocopherol transfer protein and alpha-tocopherol.
  Annals of the New York Academy of Sciences 2004 Qian J, Wilson K, Nava P, Morley S, Atkinson J, Manor D
• Light-responsive subtilisin-related protease in soybean seedling leaves.
  Plant physiology and biochemistry : PPB 2004 Barnaby NG, He F, Liu X, Wilson KA, Wilson KA, Tan-Wilson A